Journal
SUPPORTIVE CARE IN CANCER
Volume 16, Issue 8, Pages 879-889Publisher
SPRINGER
DOI: 10.1007/s00520-008-0418-0
Keywords
bone metastases; bone pain; breast cancer; prostate cancer; zoledronic acid
Ask authors/readers for more resources
Introduction Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. Discussion Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available